Fluconazole, a new oral triazole drug structurally and pharmacologically related to the imidazole antifungal agents, was recently approved for marketing in the United Kingdom. Although fluconazole itself has not been reported to inhibit phenytoin metabolism, strong circumstantial evidence suggests that this ptient's phenytoin toxicity was the result of such an interaction.
The imidazole antifungal a nts act by inhibiting the fungal demethylation ofla asterol to ergosterol, which is essential for fungal' cell wall integrity.'
The similarity of this system to the human liver's cytochrome P450 enzyme system (responsible for metabolising drugs such as cycl sporin, phenytoin, phenobarbitone, warfarin, and antipyrine) probably explains the increased ser concentrations of these drugs when given with\ ketoconazole or miconazole. Fluconazole is more selective for fungal cytochrome P450.2 At 50 mg/day for seven days it did not affect antipyrine metabolism3 (a recognised non-invasive marker of human cytochrome P450 activity and an accepted predictor of hepatic metabolism drug interactions, particularly phenytoin and warfarin) and at 100 mg/day for 14 days it did not affect serum concentrations of cyclosporin.4
We suggest, however, that this selectivity is lost when higher doses are used. At 200 mg/day for five days fluconazole has interacted with warfarin.5 Therefore at 400 mg/day we suggest that fluconazole inhibited the hepatic metabolism of phenytoin in our patient, resulting in raised serum phenytoin concentrations and clinical signs of phenytoin toxicity. Fluconazole appears to show a dose related inhibition of the human cytochrome P450 enzyme system. 
